Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.

The implementation of genetic data for a better prediction of response to medications and adverse drug reactions is becoming a reality in some clinical fields. However, to be successful, personalized medicine should take advantage of an informational structured framework of genetic, phenotypic and environmental factors in order to provide the healthcare system with useful tools that can optimize the effectiveness of specific treatment. The impact of personalized medicine is potentially enormous, but the results that have so far been gathered are often difficult to translate into clinical practice. In this article we have summarized the most relevant applications of pharmacogenomics on diseases to which they have already been applied and fields in which they are currently emerging. The article provides an overview of the opportunities and shortcomings of the implementation of genetic information into personalized medicine and its full adoption in the clinic. In the second instance, it provides readers from different fields of expertise with an accessible interpretation to the barriers and opportunities in the use/adoption of pharmacogenomic testing between the different clinical areas.

[1]  V. Manolopoulos,et al.  Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. , 2009, Pharmacogenomics.

[2]  G. Siest,et al.  Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education , 2005, The Pharmacogenomics Journal.

[3]  V. Manolopoulos.  Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice , 2007, Clinical chemistry and laboratory medicine.

[4]  P. Kwan,et al.  Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese , 2007, Epilepsia.

[5]  Munir Pirmohamed,et al.  Adverse drug reactions in hospitals: a narrative review. , 2007, Current drug safety.

[6]  M Heath-Chiozzi,et al.  Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.

[7]  S. Tsai,et al.  Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders , 2002, Molecular Psychiatry.

[8]  D. Collier,et al.  Pharmacogenetic prediction of clozapine response , 2000, The Lancet.

[9]  J. Hauser,et al.  Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. , 2005, Pharmacological reports : PR.

[10]  C. Hiemke,et al.  CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine , 2006, Journal of clinical pharmacy and therapeutics.

[11]  H. Bozcuk,et al.  The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens , 2010, Journal of Cancer Research and Clinical Oncology.

[12]  Laszlo T Vaszar,et al.  Privacy issues in personalized medicine. , 2003, Pharmacogenomics.

[13]  D. Gurwitz,et al.  CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. , 2009, Pharmacogenomics.

[14]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[15]  E. Ruiz-Pesini,et al.  Mitochondrial pharmacogenomics: barcode for antibiotic therapy. , 2010, Drug discovery today.

[16]  D. Tregouet,et al.  Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. , 2005, Blood.

[17]  E. Bakker,et al.  Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. , 2004, Haematologica.

[18]  C. Julian‐Reynier,et al.  Genetics in clinical practice: general practitioners' educational priorities in European countries , 2008, Genetics in Medicine.

[19]  S. Kéri,et al.  Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[20]  P. Muglia,et al.  Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. , 2010, The American journal of psychiatry.

[21]  Ren Zhang,et al.  The impact of comparative genomics on infectious disease research. , 2006, Microbes and infection.

[22]  W. Koch,et al.  The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. , 2005, The Journal of clinical psychiatry.

[23]  S. Jee,et al.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.

[24]  K. Tsutani,et al.  Awareness survey of parties involved in pharmacogenomics in Japan. , 2007, Pharmacogenomics.

[25]  Insurance coverage for pharmacogenomic testing in the USA. , 2007, Personalized medicine.

[26]  C. Patrono,et al.  Determinants of the interindividual variability in response to antiplatelet drugs , 2005, Journal of thrombosis and haemostasis : JTH.

[27]  A. Egberts,et al.  VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement , 2007, Clinical pharmacology and therapeutics.

[28]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[29]  D. Schaid,et al.  SLC6A4 variation and citalopram response , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[30]  Michel G Bergeron,et al.  Rapid molecular theranostics in infectious diseases. , 2002, Drug discovery today.

[31]  R. Giugliano,et al.  Antiplatelet Therapy in Early Management of Non-ST-segment Elevation Acute Coronary Syndrome: The 2002 and 2007 Guidelines From North America and Europe , 2008, Journal of cardiovascular pharmacology.

[32]  Jaekyu Shin,et al.  Pharmacogenetics: from discovery to patient care. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[33]  J. Weitzel,et al.  Evolving perspectives on genetic discrimination in health insurance among health care providers , 2010, Familial Cancer.

[34]  H. White,et al.  Antiplatelet drug nonresponsiveness. , 2008, American heart journal.

[35]  D. Gurwitz,et al.  Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. , 2003, Trends in pharmacological sciences.

[36]  C. Flowers,et al.  The Role of Cost-Effectiveness Analysis in the Era of Pharmacogenomics , 2012, PharmacoEconomics.

[37]  A. Windemuth,et al.  Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients , 2007, Molecular Psychiatry.

[38]  M. Rieder,et al.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.

[39]  J. Weide,et al.  Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics , 2008, European Journal of Clinical Pharmacology.

[40]  Allen D. Roses,et al.  Pharmacogenetics and drug development: the path to safer and more effective drugs , 2004, Nature Reviews Genetics.

[41]  Howard L McLeod,et al.  Economic opportunities and challenges for pharmacogenomics. , 2010, Annual review of pharmacology and toxicology.

[42]  J. Keirns,et al.  Clinical pharmacology, biomarkers and personalized medicine: education please. , 2009, Biomarkers in medicine.

[43]  P. Deverka,et al.  Harnessing Economic Drivers for Successful Clinical Implementation of Pharmacogenetic Testing , 2008, Clinical pharmacology and therapeutics.

[44]  M. Ingelman-Sundberg,et al.  Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.

[45]  B. Obama,et al.  The genomics and Personalized Medicine Act of 2006. , 2007, Clinical advances in hematology & oncology : H&O.

[46]  U. Meyer.  Pharmacogenetics and adverse drug reactions , 2000, The Lancet.

[47]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[48]  C. Cusin,et al.  Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-httlpr in delusional and nondelusional depression , 2001, Biological Psychiatry.

[49]  A. Califano,et al.  Pharmacogenetics: Ethical Issues and Policy Options , 2002, Kennedy Institute of Ethics journal.

[50]  E. Smeraldi,et al.  Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine , 1998, Molecular Psychiatry.

[51]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[52]  Mark Crowther,et al.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[53]  S. Thompson,et al.  Factors affecting the maintenance dose of warfarin. , 1992, Journal of clinical pathology.

[54]  D. Kupfer,et al.  Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression , 2000, Neuropsychopharmacology.

[55]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[56]  R B Altman,et al.  The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response , 2007, Clinical pharmacology and therapeutics.

[57]  Charles DeLisi,et al.  Meetings that changed the world: Santa Fe 1986: Human genome baby-steps , 2008, Nature.

[58]  Catia Marzolini,et al.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.

[59]  M. Ansseau,et al.  Polymorphisms in the CYP 2D6 Gene: Association with Plasma Concentrations of Fluoxetine and Paroxetine , 2003, Therapeutic drug monitoring.

[60]  Wei Zhang,et al.  INHIBITION OF ADP‐INDUCED PLATELET AGGREGATION BY CLOPIDOGREL IS RELATED TO CYP2C19 GENETIC POLYMORPHISMS , 2008, Clinical and experimental pharmacology & physiology.

[61]  V. Soriano,et al.  Pharmacogenetics of tenofovir treatment. , 2009, Pharmacogenomics.

[62]  J. van der Weide,et al.  The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients , 2005, Annals of clinical biochemistry.

[63]  J. Smoller,et al.  When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR*D Study , 2009, Neuropsychopharmacology.

[64]  A. Serretti,et al.  Serotonin transporter gene associated with lithium prophylaxis in mood disorders , 2001, The Pharmacogenomics Journal.

[65]  K. Squires,et al.  Increased HIV infection rate among violent deaths: a mortuary study in the Republic of Congo , 2008, AIDS (London).

[66]  W. Hall,et al.  Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations , 2004, Journal of Molecular Medicine.

[67]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[68]  Y. Caraco,et al.  CYP2C9 Genotype‐guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study , 2008, Clinical pharmacology and therapeutics.

[69]  M. Alda,et al.  Lithium: a key to the genetics of bipolar disorder , 2009, Genome Medicine.

[70]  M. Fava,et al.  Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment , 2003, Biological Psychiatry.

[71]  Stephan Ripke,et al.  A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. , 2009, Archives of general psychiatry.

[72]  Katherine Payne,et al.  Pharmacogenetics education in British medical schools , 2008, Genomic Medicine.

[73]  K. Jain.  Role of oncoproteomics in the personalized management of cancer , 2004, Expert review of proteomics.

[74]  M. Moroni,et al.  Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  John A. Robertson,et al.  Consent and privacy in pharmacogenetic testing , 2001, Nature Genetics.

[76]  P. Harrigan,et al.  Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response , 2003, AIDS.

[77]  D. Simon,et al.  Drug-eluting stents and antiplatelet resistance. , 2008, The American journal of cardiology.

[78]  B. Horne,et al.  Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.

[79]  T. Frebourg,et al.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.

[80]  M. Farmen,et al.  Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder , 2008, Human psychopharmacology.

[81]  M. Moroni,et al.  Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.

[82]  G. Severino,et al.  Adverse drug reactions: role of pharmacogenomics. , 2004, Pharmacological research.

[83]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[84]  L. Dressler,et al.  How Will GINA Influence Participation in Pharmacogenomics Research and Clinical Testing? , 2009, Clinical pharmacology and therapeutics.

[85]  M. Pirmohamed.  Warfarin: almost 60 years old and still causing problems. , 2006, British journal of clinical pharmacology.

[86]  Dan M Roden,et al.  Genetic determinants of response to warfarin during initial anticoagulation. , 2008, The New England journal of medicine.

[87]  O. Spigset,et al.  Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers. , 2006, Journal of clinical psychopharmacology.

[88]  Felix W Frueh,et al.  From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. , 2004, Pharmacogenomics.

[89]  M. Fromm,et al.  Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. , 2008, Journal of the American College of Cardiology.

[90]  M. Gawaz,et al.  CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. , 2008, Pharmacogenomics.

[91]  D. Rujescu,et al.  Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. , 2001, The American journal of psychiatry.

[92]  B. Pace,et al.  Understanding mechanisms of γ‐globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction , 2006, Developmental dynamics : an official publication of the American Association of Anatomists.

[93]  G. Burckart,et al.  Effect of cytokine and pharmacogenomic genetic polymorphisms in transplantation. , 2008, Current opinion in immunology.

[94]  Matthias J. Müller,et al.  Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients , 2001, Schizophrenia Research.

[95]  Panos Deloukas,et al.  The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.

[96]  Michael P. King,et al.  Injection of mitochondria into human cells leads to a rapid replacement of the endogenous mitochondrial DNA , 1988, Cell.

[97]  H. Möller,et al.  Risperidone plasma levels, clinical response and side–effects , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[98]  M L Terrin,et al.  Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. , 1997, Blood.

[99]  A. Bura,et al.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.

[100]  Paul G Shekelle,et al.  Delivery of genomic medicine for common chronic adult diseases: a systematic review. , 2008, JAMA.

[101]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[102]  J Licinio,et al.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.

[103]  A. Kastrati,et al.  Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement , 2010, Circulation.

[104]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[105]  Amalia M. Issa,et al.  Ethical perspectives on pharmacogenomic profiling in the drug development process , 2002, Nature Reviews Drug Discovery.

[106]  Mark A. Rothstein,et al.  Ethical and legal implications of pharmacogenomics , 2001, Nature Reviews Genetics.

[107]  G. Schoolnik,et al.  Comparative genomics of BCG vaccines by whole-genome DNA microarray. , 1999, Science.

[108]  M. Pirmohamed,et al.  Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. , 2009, Pharmacogenomics.

[109]  Francis J McMahon,et al.  Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. , 2006, American journal of human genetics.

[110]  Different nucleotide changes in the large rRNA gene of the mitochondrial DNA confer chloramphenicol resistance on two human cell lines. , 1981, Nucleic acids research.

[111]  C. Cusin,et al.  Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. , 2002, The international journal of neuropsychopharmacology.

[112]  Kazuo Komamura,et al.  Six Novel Nonsynonymous CYP1A2 Gene Polymorphisms: Catalytic Activities of the Naturally Occurring Variant Enzymes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[113]  B. Bernhardt,et al.  What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  M. Arranz,et al.  Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research , 2007, Molecular Psychiatry.

[115]  Mariano Provencio,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[116]  D. Venzon,et al.  Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. , 2010, Pharmacogenomics.

[117]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[118]  R. Gearry,et al.  Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease , 2012, PharmacoEconomics.

[119]  S. Tsai,et al.  Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder , 2006, The Pharmacogenomics Journal.

[120]  M. Caldwell,et al.  A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. , 2005, Clinical medicine & research.

[121]  Geoffrey S. Ginsburg,et al.  The Personalized Medicine Coalition , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[122]  P. Gurbel,et al.  Aspirin and clopidogrel resistance: consideration and management. , 2006, Journal of interventional cardiology.

[123]  Judy H. Cho,et al.  Finding the missing heritability of complex diseases , 2009, Nature.

[124]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  O. Ohmori,et al.  Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6 , 2005, International clinical psychopharmacology.

[126]  Angelica Vecchio-Sadus,et al.  Toxicity of lithium to humans and the environment--a literature review. , 2008, Ecotoxicology and environmental safety.

[127]  T. Kinoshita,et al.  Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients , 2006, Neuropsychobiology.

[128]  R. Regal,et al.  Indications for Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Evidence-Based Recommendations for Use , 2008, The Annals of pharmacotherapy.

[129]  W. Newman,et al.  Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. , 2007, Pharmacogenomics.

[130]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[131]  Patricia C. Kuszler,et al.  A Review of Public Policy Issues in Promoting the Development and Commercialization of Pharmacogenomic Applications: Challenges and Implications , 2008, Drug metabolism reviews.

[132]  E. Gordon,et al.  Personalized medicine for the brain: a call for action , 2010, Molecular Psychiatry.

[133]  H. Willard,et al.  Genomic and personalized medicine: foundations and applications. , 2009, Translational research : the journal of laboratory and clinical medicine.

[134]  Jessica L Mega,et al.  Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes , 2009, Circulation.

[135]  Taylor J. Maxwell,et al.  Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes , 2008, Clinical Cancer Research.

[136]  L. Garrison,et al.  The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[137]  Thomas G Schulze,et al.  Genetic predictors of response to antidepressants in the GENDEP project , 2009, The Pharmacogenomics Journal.

[138]  J. Hughes,et al.  Trends in antimicrobial drug prescribing among office-based physicians in the United States. , 1995, JAMA.

[139]  B. Pierce,et al.  Case‐only genome‐wide interaction study of disease risk, prognosis and treatment , 2009, Genetic epidemiology.

[140]  Sandra Soo-Jin Lee,et al.  Racing Forward: The Genomics and Personalized Medicine Act , 2009, Science.

[141]  D. M. Grant,et al.  The Art and Science of Personalized Medicine , 2007, Clinical pharmacology and therapeutics.

[142]  R. Schilsky,et al.  UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.

[143]  D. Collier,et al.  Cytochrome P4502D6 genotype does not determine response to clozapine. , 1995 .

[144]  J. C. Correa,et al.  Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels , 2008, Schizophrenia Research.

[145]  L. Slaughter.  The Genetic Information Nondiscrimination Act: why your personal genetics are still vulnerable to discrimination. , 2008, The Surgical clinics of North America.

[146]  L A Farrer,et al.  Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea , 2007, The Pharmacogenomics Journal.

[147]  S. Purcell,et al.  A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. , 2009, The American journal of psychiatry.

[148]  U. Fuhr,et al.  Pharmacogenetics of Oral Anticoagulants , 2008, Clinical pharmacokinetics.

[149]  M. Skime,et al.  Assessing Attitudes about Genetic Testing as a Component of Continuing Medical Education , 2007, Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry.

[150]  Lourdes Fañanás,et al.  5-HTTLPR Polymorphism of the Serotonin Transporter Gene Predicts Non-Remission in Major Depression Patients Treated With Citalopram in a 12-Weeks Follow Up Study , 2003, Journal of clinical psychopharmacology.

[151]  F. Grosveld,et al.  Pharmacogenomics and Therapeutics of Hemoglobinopathies , 2008, Hemoglobin.

[152]  Michelle Meadows,et al.  Genomics and personalized medicine. , 2005, FDA consumer.

[153]  S. Cichon,et al.  The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. , 2010, Neuropsychobiology.

[154]  A. Serretti,et al.  Effect of 5‐HT1A gene polymorphisms on antidepressant response in major depressive disorder , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[155]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  C. Duijn,et al.  The impact of genetic testing on complex diseases , 2005, European Journal of Epidemiology.

[157]  B. Godard,et al.  Ethical implications in genetic counseling and family studies of the epilepsies , 2004, Epilepsy & Behavior.

[158]  Andrew Smart,et al.  Tailored medicine: whom will it fit? The ethics of patient and disease stratification. , 2004, Bioethics.

[159]  B. Giusti,et al.  Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis , 2010, Expert opinion on drug metabolism & toxicology.

[160]  F. Baquero,et al.  Antibiotic resistance in Spain: what can be done? Task Force of the General Direction for Health Planning of the Spanish Ministry of Health. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[161]  S. Kapur,et al.  Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. , 2009, Current pharmaceutical design.

[162]  E. Perucca,et al.  Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. , 2005, Basic & clinical pharmacology & toxicology.

[163]  A. Serretti,et al.  Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders , 2004, The Pharmacogenomics Journal.

[164]  Russ Altman,et al.  Pharmacogenomics: Challenges and Opportunities , 2006, Annals of Internal Medicine.

[165]  H. McLeod,et al.  Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. , 2009, Pharmacogenomics.

[166]  B. Lam,et al.  Erythromycin as a potential precipitating agent in the onset of Leber's hereditary optic neuropathy. , 2004, Mitochondrion (Amsterdam. Print).